American Association for Cancer Research
Browse
- No file added yet -

Supplementary Figure 2 from Expression of the miR200 Family of microRNAs in Mesothelial Cells Suppresses the Dissemination of Ovarian Cancer Cells

Download (125.71 kB)
journal contribution
posted on 2023-04-03, 14:04 authored by Kazuya Sugiyama, Hiroaki Kajiyama, Kiyosumi Shibata, Hong Yuan, Fumitaka Kikkawa, Takeshi Senga

PDF - 125K, (A) Mice were intraperitoneally injected with different amounts of recombinant adenovirus, and 2 days later, mice were sacrificed by cervical dislocation. The entire peritoneal cavity was fixed with 2% paraformaldehyde/0.2% glutaraldehyde intraperitoneally for 30 min. X-gal staining was performed, and the peritoneal cavity was opened for visual inspection. (B) X-gal-stained organs and mesothelial cells in the peritoneal cavity are shown.

History

ARTICLE ABSTRACT

The TGFβ-mediated alteration of the tumor microenvironment plays a crucial role in tumor progression. Mesothelial cells are the primary components of the tumor microenvironment for ovarian cancer cells; however, the exact role of TGFβ-stimulated mesothelial cells in ovarian cancer progression remains uncertain. In this report, we examined the effects of TGFβ-treated mesothelial cells on ovarian cancer progression. We show that TGFβ-stimulated human primary mesothelial cells (HPMC) are able to promote cancer cell attachment and proliferation and the activation of the promoter activities of MMP-2 and MMP-9, which are metalloproteinases necessary for tumor invasion. Expression of the miR200 family was downregulated in HPMCs by TGFβ stimulation, and restoration of the expression of miR200 family members in HPMCs suppressed cancer cell attachment and proliferation. Downregulation of the miR200 family by TGFβ induced fibronectin 1 production, which promoted cancer cell attachment to HPMCs. Finally, we demonstrated that the delivery of the miR200s to mesothelial cells in mice inhibited ovarian cancer cell implantation and dissemination. Our results suggest that alteration of the tumor microenvironment by the miR200 family could be a novel therapeutic strategy for ovarian cancer treatment. Mol Cancer Ther; 13(8); 2081–91. ©2014 AACR.

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC